Brad Lanoue

Mr. Lanoue is Vice President of Global and U.S. Value and Market Access Strategy at Arvinas. He has over 20 years of experience in the pharmaceutical industry, including significant experience in marketing and market access with a focus on oncology.

Mr. Lanoue joins Arvinas from Novartis, where he spent the past 24 years in roles of increasing responsibility in research, marketing, and market access. Most recently, he was a Global Disease Leader for Value and Access where his team was responsible for global reimbursement and pricing for the breast and women’s cancers product portfolio. Prior, he played an integral part in the launch of KISQALI®, a blockbuster treatment for advanced breast cancer, leading the development and execution of the Global Value and Access launch strategy for this key compound. He also held significant marketing leadership roles in the Global launch of ZYKADIA® and the U.S. launch of AFINITOR®.

Mr. Lanoue received his M.Sc. with a specialization in Developmental Genetics, and a B.Sc. in Biology, both from McMaster University in Hamilton, Ontario, Canada.